ACRS
Aclaris Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.47 / 10
Netural
Aclaris Therapeutics exhibits poor fundamentals (score 3.5/10). Key concerns include a year-over-year revenue decline of -31.3%, low interest-coverage ratio in the first quartile, and negative valuation gaps (e.g., Asset-MV -0.50). However, Days-sales-outstanding in quartile 1 offers a modest offset. Overall, the balance of factors supports a prudent stance.
Analysis Checks(6/10)
Revenue-MV
Value-2.40
Score1/3
Weight7.84%
1M Return4.24%
Value-2.40
Score1/3
Weight7.84%
1M Return4.24%
Days sales outstanding
Value72.55
Score2/3
Weight1.70%
1M Return1.10%
Value72.55
Score2/3
Weight1.70%
1M Return1.10%
Net income-Revenue
Value-0.17
Score2/3
Weight15.58%
1M Return8.45%
Value-0.17
Score2/3
Weight15.58%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.56%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.56%
1M Return-1.11%
Asset-MV
Value-0.50
Score3/3
Weight28.86%
1M Return13.15%
Value-0.50
Score3/3
Weight28.86%
1M Return13.15%
Total operating revenue (YoY growth rate %)
Value-31.32
Score1/3
Weight-1.14%
1M Return-0.79%
Value-31.32
Score1/3
Weight-1.14%
1M Return-0.79%
Profit-MV
Value0.46
Score2/3
Weight15.57%
1M Return8.45%
Value0.46
Score2/3
Weight15.57%
1M Return8.45%
PB-ROE
Value0.12
Score1/3
Weight18.95%
1M Return9.57%
Value0.12
Score1/3
Weight18.95%
1M Return9.57%
Operating revenue (YoY growth rate %)
Value-31.32
Score1/3
Weight-1.10%
1M Return-0.76%
Value-31.32
Score1/3
Weight-1.10%
1M Return-0.76%
Cash-MV
Value-0.07
Score2/3
Weight15.30%
1M Return8.41%
Value-0.07
Score2/3
Weight15.30%
1M Return8.41%
Revenue-MV
Value-2.40
Score1/3
Weight7.84%
1M Return4.24%
Value-2.40
Score1/3
Weight7.84%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-31.32
Score1/3
Weight-1.14%
1M Return-0.79%
Value-31.32
Score1/3
Weight-1.14%
1M Return-0.79%
Days sales outstanding
Value72.55
Score2/3
Weight1.70%
1M Return1.10%
Value72.55
Score2/3
Weight1.70%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight15.57%
1M Return8.45%
Value0.46
Score2/3
Weight15.57%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight15.58%
1M Return8.45%
Value-0.17
Score2/3
Weight15.58%
1M Return8.45%
PB-ROE
Value0.12
Score1/3
Weight18.95%
1M Return9.57%
Value0.12
Score1/3
Weight18.95%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.56%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.56%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-31.32
Score1/3
Weight-1.10%
1M Return-0.76%
Value-31.32
Score1/3
Weight-1.10%
1M Return-0.76%
Asset-MV
Value-0.50
Score3/3
Weight28.86%
1M Return13.15%
Value-0.50
Score3/3
Weight28.86%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight15.30%
1M Return8.41%
Value-0.07
Score2/3
Weight15.30%
1M Return8.41%
Is ACRS undervalued or overvalued?
- ACRS scores 3.47/10 on fundamentals and holds a Fair valuation at present. Backed by its -32.74% ROE, -900.01% net margin, -2.87 P/E ratio, 3.22 P/B ratio, and -203.85% earnings growth, these metrics solidify its Netural investment rating.
